These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34311462)

  • 21. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
    Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
    Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC).
    Li JJ; Zheng PCJ; Wang YZ
    World J Surg Oncol; 2017 Jun; 15(1):114. PubMed ID: 28587656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.
    Joseph B; Ji M; Liu D; Hou P; Xing M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4766-70. PubMed ID: 17911173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
    Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible roles of the xenobiotic transporter P-glycoproteins encoded by the MDR1 3435 C>T gene polymorphism in differentiated thyroid cancers.
    Ozdemir S; Uludag A; Silan F; Atik SY; Turgut B; Ozdemir O
    Asian Pac J Cancer Prev; 2013; 14(5):3213-7. PubMed ID: 23803106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression.
    Batista FA; Ward LS; Marcello MA; Martins MB; Peres KC; Torricelli C; Bufalo NE; Soares FA; da Silva MJ; Assumpção LV
    J Endocrinol Invest; 2016 Apr; 39(4):423-9. PubMed ID: 26370671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic modulators of thyroid cancer.
    Rodríguez-Rodero S; Delgado-Álvarez E; Díaz-Naya L; Martín Nieto A; Menéndez Torre E
    Endocrinol Diabetes Nutr; 2017 Jan; 64(1):44-56. PubMed ID: 28440770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
    Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
    Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.
    Lundgren CI; Hall P; Dickman PW; Zedenius J
    Cancer; 2006 Feb; 106(3):524-31. PubMed ID: 16369995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
    Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma.
    Simon D; Goretzki PE; Witte J; Röher HD
    World J Surg; 1996 Sep; 20(7):860-6; discussion 866. PubMed ID: 8678963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
    Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
    Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
    [No Abstract]   [Full Text] [Related]  

  • 34. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical management of cervical lymph nodes in differentiated thyroid cancer.
    Fritze D; Doherty GM
    Otolaryngol Clin North Am; 2010 Apr; 43(2):285-300, viii. PubMed ID: 20510715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
    Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
    BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer.
    Lee JJ; Geli J; Larsson C; Wallin G; Karimi M; Zedenius J; Höög A; Foukakis T
    Int J Oncol; 2008 Oct; 33(4):861-9. PubMed ID: 18813801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
    Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
    Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.